Lymphoma Clinical Trial
— AMENO-2Official title:
AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
Verified date | September 2009 |
Source | PETHEMA Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Ministry of Health |
Study type | Interventional |
The purpose of this trial is to determinate the security, tolerability and efficacy of aprepitant plus palonosetron versus granisetron in the prevention of nausea and emesis induced by chemotherapy in patients treated with haematopoietic progenitors transplant.
Status | Completed |
Enrollment | 196 |
Est. completion date | September 2009 |
Est. primary completion date | September 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients 18 years old or up - Will go through a Haematopoietic progenitors transplant (of mother cells from periphery blood or bone marrow with at least a 5 days long previous regime (with or without radiotherapy) - women in fertile age must give negative in the pregnancy test in serum or in urine, sensible to 25 UI of ß-hCG, in the visit before the study and accept to use a contraceptive double barrier method at least from the 14 previous days to the administration of the first dose of the study drug to the 14 following days after the last dose. - Patient has a Karnofsky punctuation =60 - Patient has an life expectancy =1 month - Patient is capable to read, understand and to complete the study questionnaires including the questions which require a visual analogy scale answer - Patient understands the study procedure and agrees to participate in it, giving his written consent. - Patient is going through one of these previous regimens: - CBV (ciclofosfamide, BCNU and VP-16) - BEAM (BCNU, VP-16, araC, melphalan) - Regimens with BUCY (Busulfan x 4 days and ciclofosfamide with or without other agents) - CYTBI (ciclofosfamide plus total body irradiation with/without others agents) Exclusion Criteria: - Patients that are in one of these situations if, according to investigator's opinion, it prevents their participation in the study. - Mental disability or emotional or psychiatric significant disorder - Patient consumes any kind of drug, included marijuana, or the investigator determines that he has excessive alcohol consumption. - Patient has any kind of infection (e.g. pneumonia) or any other uncontrolled disease (e.g. digestive obstruction) different to the process that, in the investigator's opinion, could mix the study's results or put the patient at risk if the drug is administrated. - Patient has history of hypersensitivity to granisetron, palonosetron or aprepitant. - Patient has received any non proven drug (investigation) in the last 4 weeks. - Patient has history or present history of cardiac conduction disorders specially QTC interval. Anti-arrhythmic use or electrolytic disorders capable of giving cardiac conduction disorders. - Abnormal lab values - AST >2.5 X superior limit of normality - ALT >2.5 x superior limit of normality - Bilirubin >1.5 x superior limit of normality - Creatinine >1.5 x superior limit of normality - Patients that in the 48 hours before day 1 of the study they have been treated with the following antiemetics: - 5HT-3 antagonist (ondansetron, granisetron, dolasetron, or tropisetron) - Fenotiacines - Butyrophenones: (haloperidol or droperidol) - Benzamides: metoclopramide or alizapride - Domperidone - Cannabinoids - Patient who has started to receive treatment with benzodiazepines or with opioids in the first 48 hours before the day 1 of the study, except unique daily doses of triazolam, temazepam, lorazepam and midazolam. The continuation of the chronic treatment with benzodiazepins or with opioids is authorized as long as this treatment has been initiated at least 48 hours before day 1 of the study (considering that they can increase their levels.) - Patient is taking or has taken in the 7 days before day 1 of the study the following substrates of the CYP3A4: - Terfenadine - Cisapride - Astemizol - Pimozide Or the following CYTP3A4 inhibitors - clarithromycin : azithromycin, erythromicin aroxithromycin nd are allowed - Ketoconazole or itraconazole (fluconazol is allowed) - Patient is taking or has taken in the 30 days before day 1 of the study the following substrates of the CYP3A4: - Barbiturics - Rifampicin or rifabutin - Carbamazepin or fenitoin. The administration of fenitoin as prophylaxis in regimens with busulfan of short duration is allowed in the following cases: - This is a common regimen of conditioning in the transplant: - The short time of treatment together -5 days maximum- and - With the recommendation to monitorize the levels of fenitoin (keeping in mind that the mutual interaction between aprepitant and fenitoin can decrease the level of both.) - Patient is taking or has taken in the 7 days before day 1 of the study, steroids (They can be administrated as a rescue antiemetic if it is indicated) |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario Gregorio Marañón | Madrid | |
Spain | Hospital Universitario La Paz | Madrid | |
Spain | Hospital Universitario la Princesa | Madrid | |
Spain | Hospital Clínico Universitario de Salamanca | Salamanca | |
Spain | Hospital Universitario Marqués de Valdecilla | Santander |
Lead Sponsor | Collaborator |
---|---|
PETHEMA Foundation | Merck Sharp & Dohme Corp. |
Spain,
Bosi 1993; Agura 1995; Okamoto 1996
MASCC Consensus Conference on Antihemetic Therapy, 2004)
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Determinate the security, tolerability and efficacy of aprepitant plus palonosetron versus granisetron in the prevention of nausea and emesis induced by chemotherapy in patients treated with haematopoietic progenitors transplant | 15 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Completed |
NCT01410630 -
FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
|
||
Active, not recruiting |
NCT04270266 -
Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma
|
N/A | |
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT01949883 -
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma
|
Phase 1 | |
Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT05019976 -
Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma
|
N/A | |
Completed |
NCT04434937 -
Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213)
|
Phase 2 | |
Completed |
NCT01855750 -
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
|
Phase 3 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT00775268 -
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 |